After extensive research and clinical validation, Imageens is proud to introduce CardioInspect. This marks a significant step towards providing patients with personalized and preventive medical care, ultimately striving to reshape the landscape of cardiovascular disease prevention.
As designated by the World Health Organization (WHO) as a leading cause of death, cardiovascular accidents have long presented a significant challenge despite numerous prevention initiatives. CardioInspect harnesses the power of artificial intelligence (AI) to revolutionize early prediction and prevention of cardiovascular diseases.
Built on Imageens’ Artfun+ solution, this new technology enables the identification of cardiovascular incidents up to 8.5 years in advance by assessing the rigidity of the ascending aorta using non-irradiating MRI imaging. This assessment quantifies the cardiovascular risk of the patient, allowing calculation of their real cardiovascular age from these personalized measurements.
Through close collaboration with renowned institutions such as AP-HP hospitals and the Biomedical Imaging Laboratory (INSERM/CNRS/Sorbonne University), the development of CardioInspect emerged as a technological triumph. Over four years of development and intensive clinical research, involving more than 4,000 patients and producing over 1.5 million digital images, have culminated in this pioneering solution. Imageens’ commitment to advancing cardiovascular imaging is evident through its contribution to 77 publications in reputable journals.
“CardioInspect represents a quantum leap in cardiovascular disease prevention,” stated Imageens‘ CEO. “We are driven by the desire to make a substantial impact on public health by detecting early signs of cardiovascular diseases. This predictive approach empowers healthcare professionals and patients alike to take proactive steps towards a healthier heart.”
“Practitioners can tailor their approach based on accurate risk assessments, leading to more effective and personalized prevention programs,” the Imageens’ CEO emphasized.
Imageens is a Paris-based Healthtech company founded in 2017, focusing on the prevention and early diagnosis of cardiovascular diseases (CVD). Since its inception, Imageens has been immersed in international DeepTech and established with the goal of developing market-ready medical image processing software based on over 10 years of technical and clinical research conducted by world-class research institutions such as Sorbonne Université, the AP-HP, and Johns Hopkins.
From the outset, Imageens has demonstrated its capability to harness advanced AI in creating cutting-edge medical software. This innovation has earned recognition through several prestigious French innovation competitions and multiple innovation labels.
Today, Imageens leads the charge in the rapidly growing field of AI in cardiovascular health and medical imaging. The company possesses the world’s most clinically validated technology for analyzing arterial function through MRI, deploying this technology alongside other AI components to revolutionize treatment decisions in cardiovascular health and beyond. Learn more at www.Imageens.com.